CLS Holdings (LSE:CLI) has agreed to sell its Fangdieckstrasse life sciences campus in Hamburg for €25.35m, 9% below the latest valuation. The proceeds will go towards reducing debt.

What was announced

On 29 September 2026, CLS Holdings plc (LSE:CLI) announced that it has agreed to sell Fangdieckstrasse 75, 75a and 75b in Hamburg, Germany, for €25.35m. The announcement's headline rounds the figure to €25.3m.

The property provides about 13,116 sqm (141,180 sq ft) of office, laboratory and Training space. CLS describes it as almost fully let to multiple occupiers, with a weighted average remaining Lease term of just under seven years.

The price is 9% below the property's latest valuation. The announcement does not give the valuation date or the Book Value in euros. Based on the disclosed figures, a price 9% below valuation implies a latest valuation of roughly €27.9m. That is an approximation derived from the rounded percentage, not a figure the company has published.

Background to the asset

CLS acquired the Fangdieckstrasse site in 2007. Over the years it repositioned the property by expanding its laboratory and office space and securing long-term leases, which the company says transformed it into a life sciences campus.

Chief Executive Fredrik Widlund said: "Following the successful repositioning of Fangdieckstrasse, we consider this the right time to dispose of the asset." The company presents the sale as part of its strategy of further focusing its German portfolio and reducing debt.

What is and is not disclosed

The announcement states that "proceeds from the sale will be used to pay down debt". It does not say which Facility or facilities will be repaid, or how much Debt will be cancelled.

Several details are not disclosed:

  • the buyer's identity;
  • the net initial Yield or passing rent implied by the price;
  • the valuation date and the property's book value;
  • the expected effect on CLS's loan-to-value ratio or net debt; and
  • any conditions attached to completion, beyond the expected timing.

Without the rent roll or yield, readers cannot assess from this announcement alone how the price compares with the income the asset produces. The 9% discount is measured against the latest valuation and does not indicate whether the sale produces a gain or loss against the original 2007 purchase price, which is also not disclosed.

What to watch next

Completion is expected in the fourth quarter of 2026. Points to watch include:

  • confirmation that the sale has completed, and on what final terms;
  • how much debt is repaid and which borrowings are affected;
  • the accounting effect of selling at a discount to the latest valuation, in CLS's next results; and
  • any further German disposals under the company's strategy of focusing its portfolio in that market.

Panmure Liberum and Berenberg are named as advisers in the announcement, with Edelman Smithfield handling financial PR.